2018年4月18日，青煜醫藥2018年學術系列講座在創想園舉辦。我們非常榮幸地邀請了Alex Matter博士做了題目為‘Personalized anticancer drug discovery & development in Asia’ 的學術講座。
Dr Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore. Previously, he had spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation. Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec? .